GlaxoSmithKline [GLAXO] vs Marksans Pharma [MARKSANS] Detailed Stock Comparison

GlaxoSmithKline Pharmaceuticals Ltd.

NSE
Loading...

Marksans Pharma Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: GlaxoSmithKline Pharmaceuticals Ltd. wins in 14 metrics, Marksans Pharma Ltd. wins in 6 metrics, with 0 ties. GlaxoSmithKline Pharmaceuticals Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric GlaxoSmithKline Pharmaceuticals Ltd. Marksans Pharma Ltd. Better
P/E Ratio (TTM) 41.55 23.96 Marksans Pharma Ltd.
Price-to-Book Ratio 24.80 3.20 Marksans Pharma Ltd.
Debt-to-Equity Ratio 2.09 12.24 GlaxoSmithKline Pharmaceuticals Ltd.
PEG Ratio 2.44 2.91 GlaxoSmithKline Pharmaceuticals Ltd.
EV/EBITDA 31.46 17.15 Marksans Pharma Ltd.
Profit Margin (TTM) 26.86% 12.85% GlaxoSmithKline Pharmaceuticals Ltd.
Operating Margin (TTM) 33.71% 18.08% GlaxoSmithKline Pharmaceuticals Ltd.
EBITDA Margin (TTM) 33.71% 18.08% GlaxoSmithKline Pharmaceuticals Ltd.
Return on Equity 47.54% 15.29% GlaxoSmithKline Pharmaceuticals Ltd.
Return on Assets (TTM) 22.58% 11.75% GlaxoSmithKline Pharmaceuticals Ltd.
Free Cash Flow (TTM) $12.65B $337.45M GlaxoSmithKline Pharmaceuticals Ltd.
Dividend Yield 1.65% 0.62% GlaxoSmithKline Pharmaceuticals Ltd.
1-Year Return -35.63% -2.65% Marksans Pharma Ltd.
Price-to-Sales Ratio (TTM) 11.14 3.07 Marksans Pharma Ltd.
Enterprise Value $397.44B $84.41B GlaxoSmithKline Pharmaceuticals Ltd.
EV/Revenue Ratio 10.46 3.01 Marksans Pharma Ltd.
Gross Profit Margin (TTM) 65.06% 58.08% GlaxoSmithKline Pharmaceuticals Ltd.
Revenue per Share (TTM) $224 $62 GlaxoSmithKline Pharmaceuticals Ltd.
Earnings per Share (Diluted) $60.16 $7.94 GlaxoSmithKline Pharmaceuticals Ltd.
Beta (Stock Volatility) 0.10 1.03 GlaxoSmithKline Pharmaceuticals Ltd.

GlaxoSmithKline Pharmaceuticals Ltd. vs Marksans Pharma Ltd. Stock Performance Analysis

Loading Price Chart...

GLAXO
MARKSANS

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
GlaxoSmithKline Pharmaceuticals Ltd.-0.31%-3.19%-13.28%-11.99%-17.96%-13.88%
Marksans Pharma Ltd.-1.03%5.80%20.40%51.59%31.03%38.86%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
GlaxoSmithKline Pharmaceuticals Ltd.-35.63%50.14%45.44%-39.87%-9.78%324.98%
Marksans Pharma Ltd.-2.65%181.04%197.61%488.28%10,872.61%2,742.00%

Performance & Financial Health Analysis: GlaxoSmithKline Pharmaceuticals Ltd. vs Marksans Pharma Ltd.

MetricGLAXOMARKSANS
Market Information
Market Cap i₹422.67B₹86.20B
Market Cap CategoryLarge capMid cap
10 Day Avg. Volume i42,0081,036,499
90 Day Avg. Volume i51,960832,265
Last Close₹2,115.00₹249.76
52 Week Range₹2,088.10 - ₹3,500.00₹155.00 - ₹266.60
% from 52W High-39.57%-6.32%
All-Time High₹3,872.00 (Mar 28, 2016)₹358.70 (Dec 02, 2024)
% from All-Time High-45.38%-30.37%
Growth Metrics
Quarterly Revenue Growth0.10%0.11%
Quarterly Earnings Growth0.29%0.08%
Financial Health
Profit Margin (TTM) i0.27%0.13%
Operating Margin (TTM) i0.34%0.18%
Return on Equity (TTM) i0.48%0.15%
Debt to Equity (MRQ) i2.0912.24
Cash & Liquidity
Book Value per Share (MRQ)₹100.81₹59.37
Cash per Share (MRQ)₹121.65₹14.74
Operating Cash Flow (TTM) i₹12.73B₹2.42B
Levered Free Cash Flow (TTM) i₹9.28B₹3.81B
Dividends
Last 12-Month Dividend Yield i1.65%0.62%
Last 12-Month Dividend i₹54.00₹1.40

Valuation & Enterprise Metrics Analysis: GlaxoSmithKline Pharmaceuticals Ltd. vs Marksans Pharma Ltd.

MetricGLAXO (Apr 24, 2026)MARKSANS (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i41.5523.96
Forward P/E i36.4617.29
PEG Ratio i2.442.91
Price to Sales (TTM) i11.143.07
Price to Book (MRQ) i24.803.20
Market Capitalization
Market Capitalization i₹422.67B₹86.20B
Enterprise Value i₹397.44B₹84.41B
Enterprise Value Metrics
Enterprise to Revenue i10.463.01
Enterprise to EBITDA i31.4617.15
Risk & Other Metrics
Beta i0.101.03
Book Value per Share (MRQ) i₹100.81₹59.37

Financial Statements Comparison: GlaxoSmithKline Pharmaceuticals Ltd. vs Marksans Pharma Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricGLAXO (2025)MARKSANS (2025)
Revenue/Sales i37.26B26.14B
Cost of Goods Sold i14.73B12.29B
COGS % of Revenue i39.5%47.0%
Gross Profit i22.53B13.85B
Gross Margin i60.5%53.0%
Research & Development iN/AN/A
Operating Income (EBIT) i11.14B4.56B
Operating Margin i29.9%17.4%
EBITDA i12.55B6.06B
EBITDA Margin i33.7%23.2%
Pre-Tax Income i12.60B5.04B
Pre-Tax Income % of Revenue i33.8%19.3%
Income Tax i3.32B1.21B
Income Tax % of Revenue i8.9%4.6%
Net Income (Profit) i9.28B3.83B
Profit Margin i24.9%14.6%

Balance Sheet & Liquidity Metrics

MetricGLAXO (2025)MARKSANS (2025)
Cash & Equivalents i5.39B4.96B
Total Current Assets i34.10B22.04B
Total Current Assets % of Revenue i91.5%84.3%
Total Current Liabilities i19.05B4.77B
Total Current Liabilities % of Revenue i51.1%18.3%
Long-Term Debt i24.92M2.63B
Long-Term Debt % of Revenue i0.1%10.1%
Total Shareholders Equity i19.51B24.89B
Retained Earnings i10.59B14.22B
Retained Earnings % of Revenue i28.4%54.4%
Property, Plant & Equipment i2.70B185.74M

Cash Flow Statement Comparison

MetricGLAXO (2025)MARKSANS (2025)
Operating Cash Flow i12.73B2.42B
Operating Cash Flow % of Revenue i34.2%9.3%
Capital Expenditures i-190.05M-1.72B
Free Cash Flow i12.65B337.45M
FCF Margin i34.0%1.3%
Debt Repayment iN/A-60.06M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricGLAXOMARKSANS
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i169.41M453.16M
Float Shares i41.25M214.30M
% Held by Insiders i75.65%44.06%
% Held by Institutions i7.47%18.21%
% Held by Public i16.88%37.73%

Dividend Analysis & Yield Comparison: GlaxoSmithKline Pharmaceuticals Ltd. vs Marksans Pharma Ltd.

MetricGLAXOMARKSANS
Last 12-Month Dividend i₹54.00₹1.40
Last 12-Month Dividend Yield i1.65%0.62%
3-Year Avg Annual Dividend i₹59.33₹0.72
3-Year Avg Dividend Yield i1.86%0.40%
3-Year Total Dividends i₹178.00₹2.15
Ex-Dividend DateMay 30, 2025Aug 01, 2025